<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Timing of neuraxial anesthesia during antithrombotic therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Timing of neuraxial anesthesia during antithrombotic therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Timing of neuraxial anesthesia during antithrombotic therapy</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Anticoagulant</td> <td class="subtitle1">Interval from last dose to placement/removal</td> <td class="subtitle1">Interval from placement/removal to next dose</td> <td class="subtitle1">Notes</td> </tr> <tr> <td><strong>Warfarin</strong></td> <td>4 to 5 days and verify normal INR; no monitoring needed for single dose within 24 hours of placement</td> <td> </td> <td>Continue regular neurologic evaluation until 24 hours after removal. If dosed with catheter in place, check INR daily and remove when INR &lt;1.5; if INR 1.5 to 3.0, remove catheter with caution, monitor neurologic status until INR stabilized; if INR &gt;3, hold/reduce warfarin dose. Use of other antihemostatic medications that do not influence INR may increase risk of bleeding complications.</td> </tr> <tr class="highlight_gray_text"> <td><strong>Heparin (unfractionated)</strong></td> <td> </td> <td> </td> <td>When heparin given for &gt;4 days, check platelets (risk of HIT) prior to insertion or removal.</td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Intravenous</td> <td>4 to 6 hours and verify normal aPTT</td> <td>1 hour</td> <td>Bloody/difficult needle placement may increase bleeding risk with subsequent IV heparin; use with caution.</td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Subcutaneous low dose thromboprophylaxis (5000 units subcutaneously twice per day or three times per day)</td> <td>4 to 6 hours or verify normal aPTT</td> <td> </td> <td> </td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Subcutaneous higher dose thromboprophylaxis (7500 to 10,000 units subcutaneously twice per day, total daily dose ≤20,000 units)</td> <td>12 hours and verify normal aPTT</td> <td> </td> <td> </td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Subcutaneous therapeutic (individual dose &gt;10,000 units subcutaneously or total daily dose &gt;20,000 units subcutaneously)</td> <td>24 hours and verify normal aPTT</td> <td> </td> <td> </td> </tr> <tr> <td><strong>Low molecular weight heparin (LMWH)</strong></td> <td> </td> <td>Delay LMWH 24 hours after traumatic placement</td> <td> <p>Anti-Xa level is not predictive of the risk of bleeding.</p> <p>Do not use with antiplatelet or oral anticoagulant medications as this increases risk of spinal hematoma.</p> Assess platelet count prior to NA for patients who have received LMWH &gt;4 days; SOAP consensus statement and European guidelines do not recommend platelet count.</td> </tr> <tr> <td class="indent1">Therapeutic (subcutaneous) <ul class="decimal_heading"> <li>Enoxaparin 1 mg/kg every 12 hours</li> <li>Enoxaparin 1.5 mg/kg daily</li> <li>Dalteparin 100 to 120 units/kg every 12 hours</li> <li>Dalteparin 200 units/kg daily</li> <li>Tinzaparin 175 units/kg daily</li> <li>Nadroparin 86 units/kg every 12 hours</li> <li>Nadroparin 171 units/kg daily</li> </ul> </td> <td>≥24 hours, anti-factor Xa level may be helpful<sup>*</sup></td> <td>≥4 hours after catheter removal</td> <td>Do not use therapeutic dosing with catheter in place.</td> </tr> <tr> <td class="indent1">Prophylactic (subcutaneous) <ul class="decimal_heading"> <li>Enoxaparin 30 mg every 12 hours</li> <li>Enoxaparin 40 mg daily</li> <li>Dalteparin 2500 to 5000 units daily</li> <li>Tinzaparin 3500 units daily</li> <li>Tinzaparin 50 to 75 units/kg daily</li> <li>Nadroparin 2850 units daily</li> <li>Nadroparin 38 units/kg daily</li> </ul> </td> <td>≥12 hours</td> <td> <p>First postoperative dose ≥12 hours after neuraxial procedure; subsequent dose ≥24 hours after the first dose</p> <p>For twice daily dosing: Remove catheter &gt;4 hours prior to first postoperative dose</p> For single daily dose during continuous epidural: Remove catheter 12 hours prior to next dose of LMWH, and subsequent dose should be &gt;4 hours after removal</td> <td> <p>Do not maintain epidural catheter with twice daily dosing.</p> Epidural catheter may be maintained with once daily dosing, without administration of any other antihemostatic drugs.</td> </tr> <tr class="highlight_gray_text"> <td colspan="4"><strong>Anti-factor Xa inhibitors</strong></td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Fondaparinux</td> <td> <p>ASRA: not addressed</p> European guidelines: 36 to 42 hours</td> <td> <p>6 hours</p> Remove catheter prior to first postoperative dose</td> <td>Do not administer with catheter in place. Limited clinical experience.</td> </tr> <tr> <td colspan="4"><strong>Direct oral factor Xa inhibitors</strong></td> </tr> <tr> <td class="indent1">Rivaroxaban</td> <td>3 days or measure rivaroxaban specific anti Xa level<sup>*</sup></td> <td> <p>6 hours</p> Remove catheter prior to first postoperative dose</td> <td> <p>If unanticipated administration of rivaroxaban occurs with catheter in place, withhold further doses and wait 22 to 26 hours to remove catheter, or measure rivaroxaban specific anti-Xa level.</p> FDA: Delay first dose 24 hours after traumatic puncture.</td> </tr> <tr> <td class="indent1">Apixaban</td> <td>3 days or measure apixaban specific anti Xa level<sup>*</sup></td> <td> <p>6 hours</p> Remove catheter prior to first postoperative dose</td> <td> <p>If unanticipated administration of apixaban occurs with catheter in place, withhold further doses and wait 26 to 30 hours to remove catheter, or measure apixaban specific anti-Xa level.<sup>*</sup></p> FDA: Delay first dose ≥5 hours after epidural catheter removal; Delay first postoperative dose 48 hours after traumatic puncture.</td> </tr> <tr> <td class="indent1">Edoxaban</td> <td>3 days or measure edoxaban specific anti Xa level<sup>*</sup></td> <td> <p>6 hours</p> Remove catheter prior to first postoperative dose</td> <td>If unanticipated administration of edoxaban occurs with catheter in place, withhold further doses and wait 20 to 28 hours to remove catheter, or measure edoxaban specific anti-Xa level.<sup>*</sup></td> </tr> <tr class="highlight_gray_text"> <td colspan="4"><strong>Thrombin inhibitors</strong></td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Dabigatran</td> <td> <p>CrCl &lt;30 mL/minute: avoid NA</p> <p>CrCl 30 to 49 mL/minute: 5 days</p> <p>CrCl 50 to 79 mL/minute: 4 days</p> <p>CrCl ≥80 mL/minute: 3 days</p> Renal function unknown: 5 days</td> <td> <p>6 hours</p> Remove catheter prior to first postoperative dose</td> <td> <p>If unanticipated administration of dabigatran occurs with catheter in place, withhold further doses and wait 34 to 36 hours to remove catheter, or measure dTT or ecarin clotting time.<sup>*</sup></p> May be reversed with idarucizumab if necessary.</td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Argatroban</td> <td>Avoid neuraxial techniques</td> <td> </td> <td> </td> </tr> <tr class="highlight_gray_text"> <td class="indent1">Hirudin derivative (bivalirudin)</td> <td>Avoid neuraxial techniques</td> <td> </td> <td> </td> </tr> <tr> <td colspan="4"><strong>Antiplatelet medication</strong></td> </tr> <tr> <td class="indent1" colspan="4">Platelet P2Y12 receptor blockers</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Clopidogrel</li> </ul> </td> <td>5 to 7 days</td> <td> <p>Without loading dose: immediate</p> With loading dose: 6 hours</td> <td>Neuraxial catheters can be maintained for 1 or 2 days if no loading dose will be administered.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Prasugrel</li> </ul> </td> <td>7 to 10 days</td> <td> <p>Without loading dose: immediate</p> With loading dose: 6 hours</td> <td>Neuraxial catheters should not be maintained after administration of prasugrel.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Ticlopidine</li> </ul> </td> <td>10 days</td> <td> <p>Without loading dose: immediate</p> With loading dose: 6 hours</td> <td>Neuraxial catheters can be maintained for 1 or 2 days if no loading dose will be administered.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Ticagrelor</li> </ul> </td> <td>5 to 7 days</td> <td> <p>Without loading dose: immediate</p> With loading dose: 6 hours</td> <td>Neuraxial catheters should not be maintained after administration of ticagrelor.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Cangrelor</li> </ul> </td> <td>3 hours</td> <td> <p>8 hours</p> Remove catheter prior to first postoperative dose</td> <td> </td> </tr> <tr> <td class="indent1">Platelet GP IIb/IIIa inhibitors</td> <td> </td> <td> </td> <td>Contraindicated for 4 weeks after surgery; monitor neurologic status if given after neuraxial technique.</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Tirofiban</li> </ul> </td> <td>4 to 8 hours</td> <td> </td> <td> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Eptifibatide</li> </ul> </td> <td>4 to 8 hours</td> <td> </td> <td> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Abciximab</li> </ul> </td> <td>24 to 48 hours</td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Cilostazol</td> <td>2 days</td> <td> <p>6 hours</p> Remove catheter ≥6 hours prior to first postoperative dose</td> <td> </td> </tr> <tr> <td class="indent1">Dipyridamole</td> <td>24 hours</td> <td>Remove catheter ≥6 hours prior to first postoperative dose</td> <td> </td> </tr> <tr> <td class="indent1">Aspirin</td> <td>May continue dosage</td> <td>May continue dosage</td> <td>Affects platelet function for the life of the platelet (up to 7 days). Avoid neuraxial techniques on aspirin if early postoperative use of other anti-hemostatic drugs (including heparin) is anticipated.</td> </tr> <tr> <td class="indent1">NSAIDs (nonsteroidal antiinflammatory drugs)</td> <td>May continue dosage</td> <td>May continue dosage</td> <td>Effect on platelet function normalizes within 3 days. Avoid neuraxial techniques on NSAIDs if early postoperative use of other anti-hemostatic drugs (including heparin) is anticipated. COX-2 inhibitors (celecoxib) have minimal effect on platelet function.</td> </tr> <tr class="highlight_gray_text"> <td><strong>Herbal medications (garlic, ginkgo, ginseng)</strong></td> <td>May continue dosage</td> <td>May continue dosage</td> <td>Concurrent use with other anti-hemostatic drugs may increase bleeding risk.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Recommendations in this table reflect those that appear in the guidelines of the ASRA fourth <span style="white-space: nowrap;">edition<sup>[1]</sup>,</span> unless otherwise specified.</div><div class="graphic_footnotes"><p>aPTT: activated partial thromboplastin time; 
        ASRA: American Society of Regional Anesthesia and Pain Medicine; 
        CrCl: creatine clearance; 
        FDA: US Food and Drug Administration; 
        HIT: heparin-induced thrombocytopenia; 
        INR: international normalized ration; 
        IV: intravenous; 
        NA: neuraxial anesthesia; 
        PT: prothrombin time; 
        P2Y12: purinergic receptor P2Y.</p>
    
    * Safe levels other than zero have not been determined.</div><div class="graphic_reference">Data from:
    <ol>
<li>Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med 2018; 43:263.</li>
<li>Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition): Erratum. Reg Anesth Pain Med 2018; 43:566.</li>
</ol></div><div id="graphicVersion">Graphic 87862 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
